Saturday Morning Breakfast Cereal - Capital
Dec. 8th, 2025 11:20 am
Click here to go see the bonus panel!
Hovertext:
Later, as a matter of principle, they have a 1 to 1 sex to children ratio.
Today's News:

Hovertext:
Later, as a matter of principle, they have a 1 to 1 sex to children ratio.
A final deciding factor was that if Wimsey did not spend Christmas at Fenchurch, he would have no decent excuse for not spending it with his brother's family at Denver, and of all things in the world, a Christmas at Denver was most disagreeable to him.
Accordingly, he looked in at Denver for a day or two, irritated his sister-in-law and her guests as much as, and no more than, usual and thence, on Christmas Eve, made his way across country to Fenchurch St Paul.
"They seem," said Wimsey, "to keep a special brand of disgusting weather in these parts." He thurst up his hand against the hood of his car, discharging a deluge of water. "Last time it was snowing and now it's pelting cats and dogs. There's a fate in it Bunter."
"Yes, my lord," said that long-suffering man. He was deeply attached to his master, but sometimes felt his determined dislike of closed cars to be a trifle unreasonable. "A very inclement season, my lord."
Rivers of London is an urban fantasy series written by Ben Aaronovitch (a Doctor Who writer). So far, it includes 9 books and loads of novellas. Set in almost-present-day London (IIRC the first book is set in 2011, the latest in 2018), I've heard it once described as "Harry Potter meets your standard British police procedural", and as back-cover blurb descriptions go it's not bad. It's just so much more than 'magic coppers', though.
The books are written in first-person and our POV character is Peter Grant, a mixed-race police constable and born-and-bred Londoner, with a touch of ADHD and the best British sense of humour. The books work because Peter is so damn likeable. Mind you, the books are also very British, which might be a selling point, if you're me, or put you off. The first seven books conclude a story arc, Aaronovitch knows how to play the long game, and are damn near perfect IMO.
The Rivers of London fandom used to be small but very active, but in recent years some people drifted away from it because they found it a bit uncomfortable to be fans of a series where the police is considered a force of good, I think. And I understand why. I am Italian, from Genova, I wouldn't be able to suspend my disbelief to read about Italian police being good guys (if you don't know what I'm talking about look up what happened during the 2001 G8 in my town). However, I have no problems romanticising bits of another country's police force, when they are represented by the likes of Peter Grant, Sahra Guleed and Thomas Nightingale. I'm afraid I'm not doing a good job of describing how awesome the series, is so I'll leave you with this introductory post by
sixthlight, who was the BNF back then.
It's a new day [vid] by pollyrepeat. This awesome fanvid can totally work as a trailer for the series. I'm always so in awe of fans who can make vids for a canon which has no footage to offer as a starting point.
Longhouse by philomytha. This is such a great example of Peter's narration, and a casefile fic, and also a good example of the predictable main ship: Peter/Nightingale.
This(not) be the verse by leupagus. 3.8 K words.
"Be honest, sir," I said, scrabbling for the left flipper, "I look like a moron."
"I’ve seen you look moronic before, Peter," Nightingale said, flicking the wheel right and sending us careening down a side street and me thudding against the left-hand door. "This does not even, as you put it, 'crack the top ten.'"
This is my fave of the most recent fics. It's got spoilers for, let's say, a development in Peter's life in the last two books? If you've read the books, you know what I'm talking about. Perfect Peter's voice and great interaction with Nightingale (totally non shippy). There are two podfic versions available! Haven't listened to either yet, but I plan on doing that asap.
I've Found a New Baby by knight-tracer and
thefourthhvine. 13.6k. Peter/Nightingale. It's a sort of self-contained casefile of sorts, it can fit pretty much anywhere in canon before the last two books, I think, it's been a while since I listened to it. It's not particularly spoilery, I think. Peter finds a baby on the doorstep of the Folly.
It’s an embarrassing cliché, I know, but there was an actual basket, made of what looked to be actual wicker, actually sitting there. It was oval and large and had spaces for handholds on either end; for a minute, I thought it was full of laundry, and my mind spun an image of a ghost laundress. Then the small hand emerged from the basket, waved around for a minute, and smacked down again.
Brilliant Peter's voice and even better Nightingale's characterisation. The podfic is excellent!
Saving the big guns for last...As I said,
sixthlight was the BNF in the fandom, for a reason. All her works are amazing. I miss her fic like crazy. Anyway, my all-time favourite is this:
Wizardry by Consent. 62K words. It's an AU,a canon divergence one, and it's best enjoyed if you know canon to be able to appreciate the amazing worldbuilding and character work the author does when she takes our beloved characters on a new journey, starting from a simple change to the canon: Peter never became the Nightingale apprentice.
Fifteen years after a headless body was discovered in Covent Garden, Thomas Nightingale is still the last wizard in Britain, and Peter Grant, newly appointed Commander for Community Engagement in the Metropolitan Police Service, has just learned the truth about the existence of the Folly. He has one or two questions. The podfic by lazulus is [insert superlative adjective of your choice here].
The Pitt
hard odds to beat when you're on all fours by loveism. Mel/Trinity. Femslash at its finest, perfectly in character and so well-written. I love me some Trinity Santos when people know how to write her well, and damn, Mel deserves all the good sex, so...
Margaret Atwood seems to be claiming some kind of unusual prescience for herself when writing The Handmaid's Tale:
Speaking on BBC Radio 4’s Desert Island Discs, Atwood said she believed the plot was “bonkers” when she first developed the concept for the novel because the US was the “democratic ideal” at the time.
I think the idea of a fundamentalist, patriarchal, misogynist backlash was pretty much in people's minds?
I've just checked a few dates.
At least one of the potential futures in Marge Piercy's Woman on the Edge of Time (1976).
Margaret O'Donnell's The Beehive (1980) .
Suzette Haden Elgin's Native Tongue (1984) and sequels.
Various short stories.
Various works by Sheri Tepper.
I'm probably missing a lot.
And assorted works in which there was an enclave or resistance cell of women embedded in a masculinist society.
I honestly don't think a nightmare which was swirling around at the time is something that can be claimed as woah, weird, how did I ever come up with that?
I'm a bit beswozzled by the idea that in the early-mid 80s the USA was a shining city on a hill, because I remember reviewing a couple of books on abortion in US post-Roe, and it was a grim story of the erosion of reproductive rights and defensive rearguard actions to protect a legal right which could mean very little in practice once the 1977 Hyde Amendment removed federal funding, and an increasingly aggressive anti-choice movement.
In November, Fanlore ran the Fanlore No Fault November challenge: a catch-up event for earlier badges editors missed! The challenge ran from November 16 to 30, with many editors participating and earning badges from previous months.
Curious about editing Fanlore? Check out the New Visitor Portal and Tutorial for getting started!
On November 14, we celebrated AO3’s 16th anniversary! \o/
Accessibility, Design & Technology continued to prepare emails for translation and improved how the download and chapter index menus behave with each other on smaller screens.
AO3 Documentation updated the Contacting the Staff FAQ.
Open Doors finished importing Oz Magi, an Oz annual gift exchange, and Stayka’s Saint Seiya Archive, a Saint Seiya archive. They also shared an annual roundup of the fanzine collections created in the last year for fanworks imported through the Fanzine Scan Hosting Project (FSHP) and announced the upcoming import of a Harry Potter archive, PhoenixSong.
In October, Policy & Abuse received 5,061 tickets, setting a record high for the third month in a row. Support received 3,043 tickets. Tag Wrangling wrangled over 600,000 tags, or over 1,380 tags per wrangling volunteer.
Tag Wrangling also continues to create new “No Fandom” canonical tags and announced a new batch of tags for November.
TWC continues to prepare for the two upcoming 2026 special issues: “Disability and Fandom” and “Gaming Fandom”. The submission deadline for the two 2027 special issues, “Music Fandom” and “Latin American Fandoms”, is also quickly approaching on January 1.
In November, the OTW filed an Amicus brief in the United States Supreme Court, arguing that the Supreme Court should clarify the rules surrounding who can challenge a trademark registration application. In a case involving whether someone should own the trademark “Rapunzel” for dolls of the character Rapunzel, the OTW argued that the Trademark Office should consider the interests of the public—including fans—in deciding whether to award private ownership over a word or symbol that may be in the public domain.
Legal also worked with Communications on a news post about recent legislation and have responded to a number of comments and queries on this post and other issues.
Board continued work on annual turnover and meeting with all committees. They made progress on the OTW Procurement Policy and expected to get it finalized soon. They, along with the Board Assistants Team, also continued to work with Volunteers & Recruiting and Organizational Culture Roadmap on the ongoing Code of Conduct review.
Development & Membership has been catching up on post-Drive tasks.
December 5 was International Volunteers Day! As a volunteer-run organization, the OTW would not be possible without the support and diligence of our volunteers. We thank all our volunteers, past and present, for the work they’ve contributed to the OTW.
If you’re curious about volunteering for the OTW, we recruit for various positions on a regular basis, and recruitment will next open in January.
From October 25 to November 22, Volunteers & Recruiting received 287 new requests, and completed 270, leaving them with 63 open requests (including induction and removal tasks listed below). As of November 22, 2025, the OTW has 983 volunteers. \o/ Recent personnel movements are listed below.
New Fanlore Volunteers: Luana and 2 other Chair-Track Volunteers
New Policy & Abuse Volunteers: Anderson, Araxie, corr, Aspenfire, Klm, Mothmantic, Nova Deca, vanishinghorizons, and 1 other Volunteer
New Tag Wrangling Volunteers: 90Percent Human, Aeon, Alecander Seiler, ambystoma, Astrum, Atlas Oak, batoidea, Bette, Bottle, bowekatan, Bruno, Chaosxvi, Destiny, DogsAreTheBest312, Dream, elia faustus, Ellexamines, Elliott W, Gracey, jacksonwangparty, Jean W, Kalico, Keira Gong, Kiru, lamonnaie, Lavender, Loria, Lucia G, LWynn, Max, Nikki, Nioral, noctilucent, Our Hospitality, Primo, Rie, Salethia, Sapphira, sashene, Schnee, Scylle, sneakyowl, soymilk, Thaddeus, TheCrystalRing, thewritegrump, Water, Wintam, yucca, and 1 other Tag Wrangling Volunteer
New Translation Volunteers: 1 Translator
New TWC Volunteers: Lys Benson (Copyeditor)
New User Response Translation Volunteers: Cesium (Translator)
Departing AO3 Documentation Volunteers: 1 Editor
Departing Open Doors Volunteers: Irina, Paula, and 2 other Import Assistants; 1 Administrative Volunteer, and 1 Fan Culture Preservation Project Volunteer
Departing Policy & Abuse Volunteers: 1 Communications News Post Moderation Liaison
Departing Tag Wrangling Volunteers: Julia Santos (Tag Wrangling Supervisor); blackelement7, pan2fel, and 7 other Tag Wrangling Volunteers
Departing Translation Volunteers: weliuona and 2 other Translators
Departing Volunteers & Recruiting Volunteers: Alisande and 2 other Volunteers
For more information about our committees and their regular activities, you can refer to the committee pages on our website.

Which of these look interesting?
New Edge Sword & Sorcery Magazine: Volume I, Number 5 edited by Oliver Brackenbury (December 2025)
3 (42.9%)
New Edge Sword & Sorcery Magazine: Volume I, Number 6 edited by Oliver Brackenbury (December 2025)
2 (28.6%)
New Edge Sword & Sorcery Magazine: Volume I, Number 7 edited by Oliver Brackenbury (December 2025)
2 (28.6%)
Black River Ruby by Jean Cottle (January 2026)
2 (28.6%)
The Flowers of Algorab by Nils Karlén, Kosta Kostulas, and Martin Grip (January 2026)
5 (71.4%)
Headlights by C J Leede (June 2026)
1 (14.3%)
Some other option (see comments)
0 (0.0%)
Cats!
5 (71.4%)
I see you—standing in the grocery store line, eyeing that pack of ground beef and two kinds of cheese, wondering if tonight’s comfort food is about to wreck your budget. Go ahead and put them back, friend! This Vegan Lasagna recipe is here to save dinner (and your wallet). It’s hearty, surprisingly creamy, and packed with serious plant-based protein thanks to a powerhouse mix of tofu, lentils, and beans. You’ll get all the cozy, saucy, layered goodness of classic lasagna, just without the price tag or the meat. Trust me, this budget-friendly, dairy-free lasagna is proof that you don’t have to spend big to eat big.

Using everyday vegan staples like lentils, tofu, beans, and walnuts, this recipe is layer after layer of plant-based goodness. I make a homemade “ricotta” from tofu and cannellini beans, build a hearty meatless filling with lentils, mushrooms, sun-dried tomatoes, and walnuts, and tuck them between layers of marinara, spinach, and lasagna noodles. Everything comes together with a deep, umami flavor that makes each slice feel extra cozy and satisfying.
But what is umami, you ask? Umami is the savory “fifth taste” that makes food crave-worthy! And you don’t need meat to get umami! The tomatoes, mushrooms, and walnuts I use in this recipe bring it naturally. Even better, this whole pan lands at about 180 grams of protein total for roughly $15, which beats our already budget-friendly meat-and-cheese lasagna when you compare the price per serving. And the higher cost of meat and dairy can really make those prices jump!
All this to say, it doesn’t matter if you’re vegan, dairy-free, or just craving a lighter version of your favorite comfort food; this homemade vegan lasagna hits all the right notes.

See how we calculate recipe costs here.

Gather all of your ingredients and preheat the oven to 375°F.

Prep the lentil layer: Cook the lentils by bringing 3 cups of water, ½ cup of lentils, and 1 tsp salt to a boil. Once boiling, lower the heat and let them simmer for about 15-20 minutes, or until they’re cooked but not falling apart or mushy. Drain any remaining liquid and set them aside.

Place ¼ cup sun-dried tomatoes, ¼ cup walnuts, and 8 oz. white mushrooms in a food processor.

Pulse several times until everything is finely chopped and evenly combined. You’re aiming for a texture similar to hand-minced vegetables. Pause to scrape down the bowl whenever needed so everything gets processed evenly.

Cook the noodles: Meanwhile, bring a large pot of water to a boil and cook 16 oz. lasagna noodles for 8-10 minutes, or until just al dente. They’ll soften more in the oven. Toss the noodles with 1 tsp olive oil to prevent sticking, then keep them covered with a clean towel or the pot lid so they are less likely to stick together and dry out.

Sauté the mushroom mix: Warm 1 Tbsp of the reserved sun-dried tomato oil (or olive oil, if using dry-packed tomatoes) in a sauté pan over medium-low heat. Stir in ½ tsp salt and the mushroom mixture. Let it cook slowly, checking in from time to time, while you move on to the next steps. The mushrooms will release moisture, then absorb it again as they continue to cook, so keep an eye on things to avoid burning.

Make the tofu ricotta: Meanwhile, break up 1 lb. block extra firm tofu (strain excess water and give each piece a gentle squeeze over the sink, but no need to press the tofu—a little moisture is good for this recipe!) Add the tofu to the food processor along with ½ tsp salt, 1 Tbsp lemon juice, 1 Tbsp Italian herb seasoning, the entire 15.5 oz. can of white beans with its liquid, 4 garlic cloves, and 1 tsp black pepper.

Process until everything blends into a smooth, ricotta-like mixture with no lumps.

Finish the lentil layer: Add 1 Tbsp Italian herb seasoning, the cooked lentils, and 14.5 oz strained petite diced tomatoes to the sauté pan with the mushroom mixture. Cook for another 5 minutes, stirring occasionally, until everything is well combined and fragrant.

Assemble the vegan lasagna: Spread a thin layer of marinara sauce across the bottom of a 9×13-inch baking dish, just enough to lightly coat the surface.


Lay down your first layer of noodles, slightly overlapping them so they form a continuous base. Then, spoon out half of the tofu ricotta and spread it gently and evenly over the noodles. The mixture is thick, so take your time.


Scatter the spinach evenly over the ricotta layer. Add another layer of noodles. Depending on your dish, you may need an extra noodle as you move upward and the pan widens.


Next, spoon on a generous amount of marinara sauce. Spread the entire lentil mixture over the sauce, smoothing it out so it’s evenly distributed.


Add another layer of noodles and spread the remaining tofu ricotta on top.


Add one final noodle layer, then cover the top with the rest of the marinara sauce. Sprinkle 1 tsp freshly minced parsley and 1 Tbsp freshly minced basil over the surface.

Bake: Cover the dish with foil and bake for 40 minutes. Remove the foil and bake for another 10 minutes to finish. Let it cool for about 10 minutes, then serve and enjoy!

I love serving this tofu lasagna with a bright side like my zucchini and corn salad (just skip the Parmesan to keep it vegan) and a slice of homemade garlic bread made with vegan butter. If you don’t fancy a salad, I also like a serving of sautéed green beans or roasted butternut squash to make the meal feel extra warm and cozy.
Keep leftovers stored in an airtight container in the fridge for up to 3–4 days. Reheat individual portions in the microwave or warm them in a covered dish in the oven at 350°F until heated through.
You can also freeze this vegan lasagna for up to three months, either as a whole pan or in individual portions wrapped well and tucked into a freezer-safe container or bag. Just keep in mind that cooked tofu can become denser once frozen and thawed. The mushroom layer may also release some liquid, so freezing is best if you don’t mind some texture changes. Let it thaw overnight in the fridge before reheating.
The post Vegan Lasagna appeared first on Budget Bytes.
On the Friday after Thanksgiving, Vinay Prasad, the FDA’s top vaccine regulator, made a claim that shocked the public-health establishment. “For the first time,” he wrote in a leaked email to his staff, “the US FDA will acknowledge that COVID-19 vaccines have killed American children.” The agency had supposedly identified at least 10 children who died from getting COVID shots.
To say the email was poorly received by vaccine experts and physicians would be an understatement. Prasad’s claim provoked a rapid series of rebuttals. A response from 12 former FDA commissioners, published in The New England Journal of Medicine on Wednesday, called Prasad’s memo “a threat to evidence-based vaccine policy and public health security.” All of the potential vaccine-related deaths reported to the government, presumably including those to which Prasad referred, had already been reviewed by the agency’s staff, the former commissioners wrote, and “different conclusions” had been reached. Elsewhere, doctors and scientists declared that absolutely no evidence links COVID-19 vaccines to death in children; and that in order to suggest otherwise, Prasad and his colleagues had engaged in an “evidence-manufacturing mission,” a “dumpster dive” for shoddy data, or—worse—a campaign of lying.
Prasad is among the public-health officials who, under the leadership of Robert F. Kennedy Jr., have been systematically undermining the nation’s confidence in immunizations. Prasad has not yet offered up any documentation to support his assertion, and his count of vaccine-related deaths may well turn out to be inflated. The memo’s overheated rhetoric and lengthy recitation of political grievances also raise some doubts about his claims.
Yet there’s something troubling—and telling—in the fact that his memo has provoked people to deny even the possibility of COVID-vaccine-related deaths. The idea that mRNA-based shots have, tragically, killed a very small number of children is not far-fetched. It also doesn’t imply a catastrophic threat to public health, given that tens of millions of doses of these vaccines have safely been given out to young people. From the start of the coronavirus pandemic, lack of nuance has been a problem with public-health messaging—one that anti-vaccine advocates have made use of to great effect. Now, in a moment when public health in America is under existential threat, this insistence that no evidence exists for vaccine-related deaths risks adding to the crisis.
No public-health authorities deny that COVID shots can have some ill effects. Adverse reactions are possible with all medical interventions. The mRNA-based vaccines produced by Pfizer and Moderna, in particular, are known to cause myocarditis—inflammation of the heart—on rare occasions, especially in teenage boys and young men. The form of myocarditis that occurs after vaccination is typically far less severe than the one caused by viruses; for unclear reasons, mRNA-related cases have largely disappeared in recent years. But this condition can be deadly, and considering the hundreds of millions of mRNA doses that have been administered to Americans, even extraordinarily unlikely outcomes may well be inevitable.
[Read: ‘It feels like the CDC is over’]
In August 2021, U.S. physicians published details of a 42-year-old man’s post-vaccination death from myocarditis in The New England Journal of Medicine. Similar cases trickled in from other countries too. South Korean researchers and public-health officials, who tracked postimmunization fatalities very closely, identified a total of 21 deaths from vaccine-induced myocarditis—all in adults—during their country’s initial COVID-inoculation campaign, which reached more than 44 million people. And in 2022, one of my former instructors, the forensic pathologist James Gill, Connecticut’s chief medical examiner, found that children could also be at risk of death. Writing in a peer-reviewed journal, he and his colleagues described the cases of two teenage boys who died of heart damage after receiving their second Pfizer dose.
So why is Prasad’s allegation that a very small number of kids have died from COVID shots being treated as some unholy aberration? I reached out to Paul Offit, a former member of the CDC’s immunization advisory committee who had described the memo’s assertions as being “fairly fantastic.” He told me that although Prasad’s claim may ultimately pan out, he does not consider the published case reports definitive, nor does he believe that the shots have led to any deaths. “It’s not terribly convincing that this vaccine killed anybody,” he said.
Michael Osterholm, the director of the Center for Infectious Disease Research and Policy at the University of Minnesota, gave the same response: He doesn’t think that the COVID shots have yet been linked to any deaths, and he trusts the judgment of the officials who had first reviewed these cases. (Like Offit, he allowed for the possibility that such cases might be identified in the future.)
When I reached out to Krutika Kuppalli, an infectious-disease physician who works on vaccine safety, she told me that high-quality studies from around the world have clearly demonstrated that there isn’t any wave of mRNA-related deaths. Population-level data show no increase in mortality from the Pfizer or Moderna COVID shots. This means that if the immunizations do cause death, it happens so infrequently as to be statistically undetectable. (Abundant evidence shows that the vaccines reduce mortality from SARS-CoV-2. That statistical signal is clear as day.)
[Read: Revenge of the COVID contrarians]
But there’s a disconnect among the sort of studies cited by Kuppalli and doctors’ observations on the ground. The latter may get written up in case reports of vaccine-related deaths, and although any single finding from this literature can be debatable, that doesn’t mean it ought to be ignored. Cause-of-death determinations happen every day in medicine, based on the most likely explanation of the facts. Yet when vaccines might be involved, that standard seems to change: Suddenly, authorities demand an impossibly high level of evidence.
Experts told me that any of the published cases of death from an mRNA vaccine could have resulted from some alternative cause, such as a preexisting condition or hidden infection. True enough, but these cases were thoroughly investigated. Many of the diagnoses were confirmed by autopsy, which is considered the gold-standard diagnostic approach. The 21 Korean deaths, in particular, were verified by a panel of specialists in cardiology, infectious disease, and epidemiology. Surely these, at least, should meet the bar for establishing a person’s cause of death—but the doctors and public-health professionals I spoke with for this story insisted that such reports don’t amount to slam-dunk proof. “These are important for hypothesis generation and mechanistic understanding,” Kuppalli said, “but they do not establish causality for death.”
Many mainstream experts have been drawing from the same playbook that COVID skeptics used at the height of the pandemic. Five years ago, they and others asked: Were thousands of American children truly getting hospitalized for COVID, or did they get hospitalized for some other reason and just happened to have COVID? Now we get a similar question: Did the teenagers who died after getting their Pfizer shots die from COVID vaccination, or did they just happen to die from something else after having been vaccinated?
The CDC itself has at times adopted this turbocharged incredulity. After Gill’s team published about the two teens, who died after receiving mRNA vaccines in the spring or summer of 2021, Tom Shimabukuro, then a high-level official in the CDC’s Immunization Safety Office, and several other agency staffers wrote a scathing letter to the journal, claiming that important facts had been omitted. They said the agency had found laboratory evidence of infection—a virus in one case and a bacterium in the other—and that at least the latter “suggested an alternate cause of death” that should have been mentioned in the paper.
[Read: Mortality numbers may have more to do with politics than science]
The CDC’s critique, however, was premised on errors so rudimentary that any trained pathologist should be able to spot them: The PCR test used to detect the virus in one case is known to be unreliable for determining a true infection, for example; the bacteria implicated in the other typically grow only after a patient is deceased. Given the flimsy reasoning behind the CDC’s rebuttal, Gill’s cases could easily be among the 10 deaths that the FDA is now touting. Yet according to a June 2025 presentation by the director of the CDC’s Immunization Safety Office, “no known deaths or cardiac transplants” were seen in individuals ages 12 to 29 with post-vaccine myocarditis from January to November 2021. Another slide said there was “no increased risk of death following mRNA COVID-19 vaccines.” (Neither the Department of Health and Human Services nor Shimabukuro responded to questions about this story.)
Some defensiveness about the data on vaccine-related harms is understandable. Anti-vaccine activists, the HHS secretary among them, have spent years stoking unfounded fears about mRNA vaccines; doing so has almost certainly resulted in otherwise preventable deaths among those who refused to get vaccinated. And it may well be that this administration’s claims about the harms from COVID shots are unfounded, and that no persuasive evidence will ever be provided. (The FDA has indicated that supporting data will be released later this month.) But given what is already known, the public-health establishment should be prepared for the alternative. Accepting and acknowledging reasonable proof of that reality would be an important part of effectively combating the government’s current vaccine skepticism. How can medical professionals discuss the favorable risk-benefit profile of these shots if they aren’t willing to acknowledge their worst risk? Denial also creates opportunities for those who want to break the system to rebuild it. In his memo, Prasad presents a very small number of allegedly catastrophic events as a revelation of such grave importance that “swift action” must be taken in regard to the COVID vaccines and the immunization approval process overall.
The possibility—perhaps the likelihood—that a handful of vaccine-related deaths occurred and were downplayed by medical authorities does not undermine the fact that COVID vaccination, on the whole, has prevented death on a massive scale. Nor does it justify sweeping changes to vaccine regulations. Rather, it suggests the need for some targeted reforms, such as improvements to the country’s vaccine-adverse-event reporting system—and also tells us that a strategy of minimizing tragic outcomes, however rare, may not be the best way to protect a vital instrument of public health.
Updated at 11:35 a.m. ET on December 8, 2025
For a decade after its discovery, CRISPR gene editing was stuck on the cusp of transforming medicine. Then, in 2023, scientists started using it on sickle-cell disease, and Victoria Gray, a patient who lived with constant pain—like lightning inside her body, she has said—got the first-ever FDA-approved CRISPR gene-editing treatment. Her symptoms vanished; so did virtually everyone else’s in the clinical trial she was a part of.
This year, the technology has started to press beyond its next barrier. Most of the 8 million people globally who have sickle-cell disease share the same genetic mutation; treating rare disorders will require dealing with many different mutations, even within the same disease. And although rare diseases affect 30 million Americans in total, relatively few people are diagnosed with each one. Fyodor Urnov, the scientific director of UC Berkeley’s Innovative Genomics Institute (IGI), showed me a list of rare diseases and pointed to one carried by only 50 people. “Who’s going to work on a disease with 50 patients?” he asked. And even within one disorder, each person might need their own customized CRISPR treatment. Drug developers have little financial incentive to spend years and millions of dollars designing therapies that may need to be tailored to literally one person.
The technology is ready to treat at least some of these diseases, though. “There’s a whole toolbox now that can target arguably any part of the genome pretty precisely,” Krishanu Saha, a gene-editing researcher at the University of Wisconsin at Madison, told me. If researchers could build one CRISPR platform for a single disease, or even several similar ones, and tweak that template to suit each patient, they could target extremely rare disorders more quickly and economically. Maybe the first patient’s treatment for a disease takes $2 million and a year of development; by the third patient, the cost should be down to, say, $100,000 and a month of development, Urnov said, because you’ve already proved that the reused components are safe.
“We have been moving in the direction of thinking about CRISPR as a platform for some years,” Jennifer Doudna, the IGI’s founder, who shares the Nobel Prize for discovering CRISPR gene editing, told me. But, in her mind, 2025 was the first time many people understood its potential. A baby named KJ Muldoon is a big reason why.
In February, Muldoon became the first child to receive one of these customized CRISPR gene-editing treatments, tailored to fix his specific mutation. People born with his rare genetic disease, a type of urea-cycle disorder, have about a 50 percent chance of living past infancy. If they do, they live with extreme developmental delays and usually require a liver transplant. But when he was six months old, Muldoon got his bespoke treatment, and now he’s a healthy 1-year-old. His therapy was proof that custom gene-editing treatments can work and that they can be spun up relatively quickly, yet safely.
His treatment also gives scientists a chance to try the platform approach. The next child treated for a urea-cycle disorder should now be able to receive a CRISPR treatment from Muldoon’s template, tweaked to their unique DNA. CRISPR technology uses guide RNA, a molecular GPS of sorts, to send an editor protein to a particular address in someone’s DNA. Targeting a different mutation just means changing the address. Muldoon’s case put more momentum, too, behind personalized gene editing in general. The federal government recently announced two major programs that offer funding to scientists working on personalized treatments for rare diseases. The focus now, Doudna said, is figuring out how to make customized CRISPR “available to anyone who needs it.”
For years, one of the main roadblocks has been the U.S. drug-regulatory system. Its approval processes were designed for traditional drugs that help many people, not a bespoke treatment that helps one child in Philadelphia. The FDA has considered each treatment, even for the same disease, as a different drug. Biochemically, two therapies might be the equivalent of a pizza with pepperoni and another with artichokes. But under the FDA approval process, “you go back to square one. You recertify the oven. You recertify the person who throws the disk of dough. You confirm the cheese is still safe to eat,” Urnov, who was also part of the team that designed Muldoon’s treatment, said. The FDA has been trying to change that process over the past few years, and last month, two of its top officials, Marty Makary and Vinay Prasad, announced a new drug pathway that could speed up approvals for personalized rare-disease treatments. The framework was inspired in large part by the success of Muldoon’s therapy. (The FDA did not respond to a request for comment.)
The new pathway opens the door to the platform approach that scientists have hoped to take. If researchers could prove they’d successfully treated a small number of patients for one rare genetic disease, they could continue customizing treatments for other mutations, and potentially also for similar conditions. That streamlined process could finally attract for-profit players—the best shot at actually getting these customized therapies to patients en masse, Doudna said. “If we’re able to bundle trials together so that we’re able to treat multiple related diseases without starting from scratch, that could completely change the economics of treating rare disease,” she said.
The first clinical trials in this model will begin soon. Urnov and his colleagues plan to investigate a platform for rare immune disorders; Rebecca Ahrens-Nicklas and Kiran Musunuru, the geneticists who treated Muldoon at the Children's Hospital of Philadelphia, told me they are planning to start one this winter for children with various types of urea-cycle disorder. If all goes according to plan, another child should receive a treatment based on Muldoon’s in the near future.
Working this way does put more responsibility on scientists to test their therapies thoroughly, Ahrens-Nicklas said. Gene editing can go wrong: A treatment may accidentally alter the wrong part of a patient’s DNA, or the delivery mechanism could trigger a deadly immune reaction in their body. “If you have to treat fewer subjects in order to get that approval, you want to make sure that you’re really robustly measuring the safety on those few subjects” and communicating any risks to the wider gene-editing community, she said. But done well, these trials are a major step toward getting more custom treatments out to more people.
All of the researchers I spoke with emphasized that these are early days. Because of how the current gene-editing delivery mechanisms work, scientists are mostly limited to treating disorders in the blood and liver. And researchers are focused on single diseases, or groups of similar ones, for now. Their dream would be to have a CRISPR platform that could address many disparate disorders, but the current reality is that many, many families will still go without bespoke therapies. Muldoon’s treatment “took a team of people at both nonprofits and for-profit companies in multiple countries working at a scale I have never seen before,” Doudna said. And they changed his life. His parents weren’t sure if he’d ever be able to sit upright on his own, but recently, Muldoon took his first steps. The press has dubbed him a “miracle baby.” Now miracles like his need to become commonplace.
This article originally misstated the full name of the Children’s Hospital of Philadelphia.
Summer stories had a rhythm and a pattern to them, and she knew in her belly exactly how that one should have ended: with the summer lord rising healed and radiant from his bed to catch the hand of the heroic knight who had saved him... [loc. 556]
The Summer War has the beats and the ambience of the most classic fairytales: a king with three children, a curse with unexpected consequences, a bargain with the fae (in this world known as 'summerlings') that hinges on wording, a heroic princess.( Read more... )